Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Revance Therapeutics (RVNC)

Revance Therapeutics (RVNC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,093,126
  • Shares Outstanding, K 71,830
  • Annual Sales, $ 15,330 K
  • Annual Income, $ -282,090 K
  • 60-Month Beta 1.24
  • Price/Sales 139.30
  • Price/Cash Flow N/A
  • Price/Book 10.46
Trade RVNC with:

Options Overview Details

View History
  • Implied Volatility 73.78%
  • Historical Volatility 34.16%
  • IV Percentile 34%
  • IV Rank 22.08%
  • IV High 138.48% on 09/28/20
  • IV Low 55.44% on 05/26/21
  • Put/Call Vol Ratio 0.03
  • Today's Volume 587
  • Volume Avg (30-Day) 269
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 3,051
  • Open Int (30-Day) 2,939

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -1.13
  • Number of Estimates 6
  • High Estimate -0.99
  • Low Estimate -1.22
  • Prior Year -1.34
  • Growth Rate Est. (year over year) +15.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.75 +15.21%
on 09/16/21
30.00 -1.13%
on 09/27/21
+2.36 (+8.64%)
since 08/27/21
3-Month
25.45 +16.54%
on 08/17/21
33.83 -12.33%
on 07/09/21
-1.16 (-3.76%)
since 06/25/21
52-Week
22.89 +29.58%
on 11/24/20
33.83 -12.33%
on 07/09/21
+3.59 (+13.77%)
since 09/25/20

Most Recent Stories

More News
Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021

Revance Therapeutics, Inc. (Nasdaq: RVNC) a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that it will present an ePoster with a video poster presentation...

RVNC : 29.66 (+1.78%)
Revance Presents Data on the RHA(R) Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting

--- Supports Revance's commitment to ensuring safety and efficacy of aesthetic product portfolio among diverse patient populations -

RVNC : 29.66 (+1.78%)
Beverly Hills Physicians Now Offers First FDA Approved RHA Fillers by Revance Therapeutics

/PRNewswire-PRWeb/ -- Beverly Hills Physicians is now offering , fillers made by Revance Therapeutics. The health and beauty group says the RHA Collection of fillers are the only FDA-approved hyaluronic...

RVNC : 29.66 (+1.78%)
Dermal Fillers Market Size | Hit USD 6.25 Billion by 2028 and Exhibit 10.8% CAGR

The global dermal fillers market size is expected to gain momentum by reaching USD 6.25 billion by 2028 while exhibiting an impressive CAGR of 10.8% between 2021 to 2028. In its report titled "Dermal Fillers...

AGN : 193.02 (+0.02%)
RVNC : 29.66 (+1.78%)
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 6.14% and 12.73%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?...

RVNC : 29.66 (+1.78%)
Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update

--- Aesthetic accounts increased to over 2,000 from over 1,500 in the prior quarter

RVNC : 29.66 (+1.78%)
Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release second quarter 2021 financial...

RVNC : 29.66 (+1.78%)
USD 6.64 Billion, Dermal fillers Market Size, Share, Growth, Trends, Competitive Landscape, Revenue, Forecast Report [2027]

Global Dermal Fillers Market Size| 2021 Covid-19 Impact On Healthcare Industry Global Analysis By Size, Trends, Growth, Share, Business, Key Players, Merger, Statistics, Competitive Landscape, And Regional...

AGN : 193.02 (+0.02%)
RVNC : 29.66 (+1.78%)
Revance to Participate in Upcoming Virtual Healthcare Conferences

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company's President and Chief Executive Officer, Mark...

RVNC : 29.66 (+1.78%)
Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the FDA plans to initiate its pre-approval inspection...

RVNC : 29.66 (+1.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS' peptide technology, which when combined...

See More

Key Turning Points

3rd Resistance Point 31.35
2nd Resistance Point 30.67
1st Resistance Point 30.17
Last Price 29.66
1st Support Level 28.99
2nd Support Level 28.31
3rd Support Level 27.81

See More

52-Week High 33.83
Last Price 29.66
Fibonacci 61.8% 29.65
Fibonacci 50% 28.36
Fibonacci 38.2% 27.07
52-Week Low 22.89

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar